3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
Evvnt Promotion / evvnt
Archivo
22.02.2022 - 24.02.2022Online, USA
Time: 9:00 AM - 3:30 PM
Temas de la conferencia For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.